XDx announces Blue Shield of California considers AlloMap(r) medically necessary for monitoring heart transplant rejection
In: Biomedical Market Newsletter, 2011-08-23
Zeitungsartikel
Zugriff:
Aug 17 2011 08:00 AM BRISBANE CA -- XDx Inc, a molecular diagnostics company focused on the development and commercialization of clinically differentiated, high value noninvasive gene expression tests to [...]
Titel: |
XDx announces Blue Shield of California considers AlloMap(r) medically necessary for monitoring heart transplant rejection
|
---|---|
Zeitschrift: | Biomedical Market Newsletter, 2011-08-23 |
Veröffentlichung: | 2011 |
Medientyp: | Zeitungsartikel |
ISSN: | 1064-4180 (print) |
Schlagwort: |
|
Sonstiges: |
|